Filing Details
- Accession Number:
- 0001209191-11-024688
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2011-04-27 20:19:55
- Reporting Period:
- 2011-04-26
- Filing Date:
- 2011-04-27
- Accepted Time:
- 2011-04-27 20:19:55
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1012140 | Onyx Pharmaceuticals Inc | ONXX | Biological Products, (No Disgnostic Substances) (2836) | 943154463 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1365619 | Laura Brege | C/O Onyx Pharmaceuticals, Inc. 249 East Grand Ave. South San Francisco CA 94080 | Evp, Corporate Affairs | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2011-04-26 | 10,000 | $15.44 | 49,427 | No | 4 | M | Direct | |
Common Stock | Disposition | 2011-04-26 | 8,000 | $35.00 | 41,427 | No | 4 | S | Direct | |
Common Stock | Disposition | 2011-04-26 | 2,000 | $35.01 | 39,427 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Disposition | 2011-04-26 | 10,000 | $0.00 | 10,000 | $15.44 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
52,500 | 2016-06-12 | No | 4 | M | Direct |
Footnotes
- Shares sold pursuant to a 10b5-1 plan.
- Twenty-Five percent of the shares subject to the option become exercisable 1 year from the date of grant and the remainder become exercisable at a rate of 1/48th per month thereafter.